PDF(Pubmed)
Abstract：
BACKGROUND: Social jetlag is a chronic disruption of sleep timing that is characterized by different sleep timing during workdays and free days. Social jetlag has been associated with disturbed glucose metabolism, insulin resistance, and increased risk of metabolic syndrome and type 2 diabetes. In this study, we aim to investigate whether a combination of bright light therapy in the morning, bright light reduction in the evening and sleep advance instructions for 3 weeks reduces social jetlag and if this results in improvement of glycemic and metabolic control, sleep, mood and quality of life after 3 and 12 weeks in people with prediabetes and type 2 diabetes and to assess possible mediators, compared to regular sleep habits.
METHODS: In this randomized controlled trial, 60 people with prediabetes or type 2 diabetes with > 1 h social jetlag will be recruited. The intervention consists of bright light therapy (5000 lx) emitted by Vitamine-L (Lumie, UK) for 30 min each morning, combined with the advice to follow sleep advance instructions and to wear bright light-dimming goggles every evening for a period of 3 weeks. The control group adheres to their regular sleep habits and conditions. The primary outcome is glycated hemoglobin (HbA1c) after 12 weeks comparing the intervention and control in an intention-to-treat analysis. Secondary outcomes at 3 and 12 weeks are (1) social jetlag; (2) insulin sensitivity, fasting blood glucose, glucose-lowering medication use, and frequency of perceived hypoglycemia; (3) metabolic outcomes, including body mass index (BMI), waist circumference, body fat percentage, and blood pressure; (4) mood, including depression, fatigue and anxiety (measured with questionnaires); and (5) quality of life measured using EQ5D questionnaire. To assess other factors that might play a role as possible mediators, we will measure (para)sympathetic nervous system activity assessed with ECGs and electrochemical skin conductance tests, sleep quality and sleep phase distribution assessed with a sleep measuring headband (ZMax), the Dim Light Melatonin Onset in saliva samples (in a subgroup) at 3 and 12 weeks, the feeling of satiety and satiation with a 10-cm visual analog scale (VAS), diet using a food frequency questionnaire, and physical activity using an accelerometer (ActiGraph).
CONCLUSIONS: Social jetlag can contribute to poorer glycemic control and metabolic control in those with type 2 diabetes. With this intervention, we aim to reduce social jetlag and thereby improve glycemic and metabolic control. This could offer a way to improve overall population health and to reduce the disease burden of type 2 diabetes.
BACKGROUND: ISRCTN registry ISRCTN11967109 . Registered on 9 May 2024.
METHODS: In this randomized controlled trial, 60 people with prediabetes or type 2 diabetes with > 1 h social jetlag will be recruited. The intervention consists of bright light therapy (5000 lx) emitted by Vitamine-L (Lumie, UK) for 30 min each morning, combined with the advice to follow sleep advance instructions and to wear bright light-dimming goggles every evening for a period of 3 weeks. The control group adheres to their regular sleep habits and conditions. The primary outcome is glycated hemoglobin (HbA1c) after 12 weeks comparing the intervention and control in an intention-to-treat analysis. Secondary outcomes at 3 and 12 weeks are (1) social jetlag; (2) insulin sensitivity, fasting blood glucose, glucose-lowering medication use, and frequency of perceived hypoglycemia; (3) metabolic outcomes, including body mass index (BMI), waist circumference, body fat percentage, and blood pressure; (4) mood, including depression, fatigue and anxiety (measured with questionnaires); and (5) quality of life measured using EQ5D questionnaire. To assess other factors that might play a role as possible mediators, we will measure (para)sympathetic nervous system activity assessed with ECGs and electrochemical skin conductance tests, sleep quality and sleep phase distribution assessed with a sleep measuring headband (ZMax), the Dim Light Melatonin Onset in saliva samples (in a subgroup) at 3 and 12 weeks, the feeling of satiety and satiation with a 10-cm visual analog scale (VAS), diet using a food frequency questionnaire, and physical activity using an accelerometer (ActiGraph).
CONCLUSIONS: Social jetlag can contribute to poorer glycemic control and metabolic control in those with type 2 diabetes. With this intervention, we aim to reduce social jetlag and thereby improve glycemic and metabolic control. This could offer a way to improve overall population health and to reduce the disease burden of type 2 diabetes.
BACKGROUND: ISRCTN registry ISRCTN11967109 . Registered on 9 May 2024.
摘要：
背景：社交时差是睡眠时间的慢性中断，其特征是工作日和空闲日的睡眠时间不同。社会时差与葡萄糖代谢紊乱有关，胰岛素抵抗，代谢综合征和2型糖尿病的风险增加。在这项研究中,我们的目的是调查是否在早晨结合了明亮的光疗法，明亮的光线减少在晚上和睡眠提前指示3周减少社会时差，如果这导致改善血糖和代谢控制，睡眠,3周和12周后糖尿病前期和2型糖尿病患者的情绪和生活质量，并评估可能的介质，与正常的睡眠习惯相比。
方法：在这项随机对照试验中，将招募60名患有前驱糖尿病或2型糖尿病且社交时差>1小时的人。干预包括Vitamine-L（Lumie，英国)每天早上30分钟，结合建议，遵循睡眠提前指示，每天晚上佩戴明亮的调光护目镜，为期3周。对照组坚持他们的正常睡眠习惯和条件。主要结果是在12周后在意向治疗分析中比较干预和对照的糖化血红蛋白（HbA1c）。3周和12周时的次要结果是（1）社会时差；（2）胰岛素敏感性，空腹血糖,使用降糖药物，和感知到的低血糖的频率；(3)代谢结果，包括体重指数（BMI），腰围,身体脂肪百分比，和血压；（4）情绪，包括抑郁症,疲劳和焦虑(用问卷测量)；和(5)使用EQ5D问卷测量的生活质量。为了评估可能起到调解作用的其他因素，我们将测量（对）交感神经系统活动评估与心电图和电化学皮肤电导测试，使用睡眠测量头带（ZMax）评估睡眠质量和睡眠相位分布，在第3周和第12周的唾液样本中（在一个亚组中）出现弱光褪黑素，用10厘米的视觉模拟量表（VAS）来感受饱腹感和饱腹感，使用食物频率问卷的饮食，和使用加速度计（ActiGraph）的身体活动。
结论：社会时差可能导致2型糖尿病患者血糖控制和代谢控制较差。通过这种干预，我们的目标是减少社会时差,从而改善血糖和代谢控制.这可以提供改善总体人群健康和减少2型糖尿病疾病负担的方法。
背景：ISRCTN注册表ISRCTN11967109。2024年5月9日注册。
方法：在这项随机对照试验中，将招募60名患有前驱糖尿病或2型糖尿病且社交时差>1小时的人。干预包括Vitamine-L（Lumie，英国)每天早上30分钟，结合建议，遵循睡眠提前指示，每天晚上佩戴明亮的调光护目镜，为期3周。对照组坚持他们的正常睡眠习惯和条件。主要结果是在12周后在意向治疗分析中比较干预和对照的糖化血红蛋白（HbA1c）。3周和12周时的次要结果是（1）社会时差；（2）胰岛素敏感性，空腹血糖,使用降糖药物，和感知到的低血糖的频率；(3)代谢结果，包括体重指数（BMI），腰围,身体脂肪百分比，和血压；（4）情绪，包括抑郁症,疲劳和焦虑(用问卷测量)；和(5)使用EQ5D问卷测量的生活质量。为了评估可能起到调解作用的其他因素，我们将测量（对）交感神经系统活动评估与心电图和电化学皮肤电导测试，使用睡眠测量头带（ZMax）评估睡眠质量和睡眠相位分布，在第3周和第12周的唾液样本中（在一个亚组中）出现弱光褪黑素，用10厘米的视觉模拟量表（VAS）来感受饱腹感和饱腹感，使用食物频率问卷的饮食，和使用加速度计（ActiGraph）的身体活动。
结论：社会时差可能导致2型糖尿病患者血糖控制和代谢控制较差。通过这种干预，我们的目标是减少社会时差,从而改善血糖和代谢控制.这可以提供改善总体人群健康和减少2型糖尿病疾病负担的方法。
背景：ISRCTN注册表ISRCTN11967109。2024年5月9日注册。
